Joshua M. Lang MD, MS
Post-Doctoral Oncology Resident
BS: University of Iowa (Iowa City, IA)
MS: University of Illinois (Chicago)
MD: University of Illinois (Chicago)
Prior to pursuing a medical education, he received a BS in Psychology from the University of Iowa and MS in Kinesiology at the University of Illinois. His graduate research investigated molecular mechanisms of phenotype regulation in skeletal muscle and Duchenne's muscular dystrophy. He went on to graduate from the University of Illinois at Chicago School of Medicine and joined the University of Wisconsin's Physician Scientist Track combining internal medicine residency and medical oncology fellowship. He is currently funded by the UW Medical Oncology T32 training grant and is completing coursework towards a Capstone Certificate in Clinical Research . His research interests included prostate cancer, immunotherapy, and basic and translational research of immunomodulatory drugs. He has won an ASCO merit award for work on the impact of zoledronic acid and bone loss during androgen deprivation therapy in patients with prostate cancer. During his time in McNeel lab, he received a Young Investigator Award from the Prostate Cancer foundation providing 3 years of funding support for his translational research in immunotherapy and epigenetics. In addition, he was the study chair for both a current Phase I trial with a novel histone deacetylase inhibitor and an upcoming Phase II trial in patients with advanced prostate cancer. He is now a faculty at UW as a clinical instructor. Outside of medicine, Josh enjoys spending time with his wife and sons, coaching youth soccer, hiking and martial arts.